These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6386985)

  • 1. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
    Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
    J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E.
    Ghanta VK; Hiramoto NS; Hiramoto RN
    Cancer Res; 1981 Jun; 41(6):2197-9. PubMed ID: 7237419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
    Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
    Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
    Takesue BY; Pyle JM; Mokyr MB
    Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
    Miura T; Ghanta VK; Hiramoto RN
    Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells with FC receptors in myeloma; suppression of growth and secretion of MOPC-315 by T alpha cells.
    Müller S; Hoover RG
    J Immunol; 1985 Jan; 134(1):644-7. PubMed ID: 3871117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of MOPC 104E plasmacytoma with monoclonal anti-idiotype antibodies.
    Kodama K; Ghanta VK; Hiramoto NS; Hiramoto RN
    J Biol Response Mod; 1989 Aug; 8(4):385-96. PubMed ID: 2754437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
    Shrestha K; Hiramoto RN; Ghanta VK
    Int J Cancer; 1984 Jun; 33(6):845-50. PubMed ID: 6610653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor proliferation and chemotherapy in immunosuppressed mice.
    Ghanta VK; Shrestha K; Durant JR; Hiramoto RN
    Cancer Res; 1983 Mar; 43(3):1097-100. PubMed ID: 6825081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes.
    Flood PM; Philipps C; Taupier MA; Schreiber H
    J Immunol; 1980 Jan; 124(1):424-30. PubMed ID: 6965296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
    Wang KC; Berczi I; Sehon AH
    Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocompetence status as related to growth progression of mouse MOPC-315 plasmacytoma.
    Rashid G; Ophir R; Pecht M; Ben-Efraim S
    In Vivo; 1989; 3(4):279-84. PubMed ID: 2535271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.